November 13th 2023
November is Alzheimer Awareness Month and a good time to look at common myths held by clinicians and patients alike - and the facts to refute them.
October 20th 2023
At the Clinical Trials on Alzheimer's Disease Meeting, October 24-28, the biotech company will update research on lecanemab, aducanumab, and an early-stage disease treatment.
July 28th 2023
The Alzheimer's Association chief science officer discusses release of updated diagnostic guidelines for AD, which incorporate use of plasma-based biomarkers.
July 24th 2023
The highest risk of mortality among a Danish population with dementia occurred within 2 weeks of an opioid prescription but remained significant at 180 days.
July 17th 2023
Howard Fillit, MD, cofounder/chief scientific officer of the Alzheimer Drug Discovery Foundation, says lecenumab's approval opens the door for future drug development.
Cognitive Screening in Older Adults: How they Perceive the Benefits, What they Fear Most
A majority of older adults agree that all aged ≥65 years should be screened annually for dementia; more than half significantly fear a positive result, the National Poll on Healthy Aging reports.
Alzheimer Drug Lecanemab Granted Full FDA Approval
FDA's action, based on confirmatory evidence showing slowed disease progression, follows a January 2023 accelerated approval.
FDA Approves Brexpiprazole for Agitation Associated with Alzheimer Dementia
Brexpiprazole, an atypical antipsychotic, is the first and only medication approved to treat AD-associated agitation, reported in almost half of people with the disease.
Donanemab Significantly Slows Cognitive, Functional Decline in Early Alzheimer Disease
Eli Lilly's investigational drug targeting amyloid plaque slowed clinical decline by 35% in participants with early symptomatic Alzheimer disease at 18 months, the company announced.
Daily Dose: Stress & Cognitive Function among Older Adults
Your daily dose of clinical news you may have missed.
Perceived Stress Linked to Cognitive Impairment among Older Adults in the REGARDS Study
Screening for stress among older adults who present to primary care with signs of cognitive impairment could be key to reducing risk and targeting intervention, study authors say.
Daily Dose: Vaccine-preventable Viruses & Neurodegenerative Disease
Vaccine-preventable Viruses Associated with Increased Risk for Neurodegenerative Disease: NIH Findings
The large biobank-based study found 22 pairings of a neurodegenerative disorder and a previous viral infection. Vaccines exist against several of those viruses.
Dementia Risk in Older Women Reduced with More Vigorous Physical Activity, More Daily Steps
Accelerometer-measured physical activity and steps were associated with as much as a 60% lower risk of Alzheimer's disease and related dementias in a new study.
Cardiometabolic Diseases and Dementia Risk Show Dose-dependent Relationship in Large Twin Study
For each cardiometabolic disease, the risk of all-cause dementia rose by 42%; the risk rose 26% for Alzheimer disease and 64% for vascular dementia. Temporal onset and genetics play key roles.
Eisai Seeks Traditional FDA Approval for Lecenemab with Supplemental BLA Filing
Approval of lecanemab under FDA's accelerated pathway requires the company to provide phase 4 study evidence to confirm the agent's clinical effect.
Daily Dose: Variable BMI Pattern May Serve as Indicator for Dementia
Variable BMI Pattern in Midlife May Serve as Indicator for Dementia in Late Life
Variable BMI patterns across the lifespan may be a prodromal marker of dementia; a pattern of midlife increase followed by decrease was associated with greatest risk.
FDA Awards Accelerated Approval to Aducanumab for Alzheimer Disease
The FDA approved today the first drug that targets the pathophysiolgic process responsible for Alzheimer disease and the first drug since 2003 to be approved for any Alzheimer treatment.
The Skinny on Dementia and Being Skinny
Underweight means highest risk, say researchers.
Beer Brews Up Good Medicine for the Brain
This adult beverage may actually provide health benefits, specifically for Alzheimer, Parkinson, and other neurological conditions.
Poor Sleep May Add to Dementia
Previous studies have shown a link between sleep stages and mental decline. This is the first to show that certain sleep features are related to brain changes.
The Obesity and Dementia Link
Growing evidence suggests a link between obesity and dementia, but risk may be heightened or lowered, depending on age. In this study, early to mid-life obesity was linked with increased risk of later dementia.
Respiratory Diagnoses Missed, Alzheimer Biomarkers, and More
In the news: respiratory disease underdiagnosed, Alzheimer biomarkers, Crohn disease microbiome, migraine device, sleep apnea and diabetes.
Vitamin E Slows Functional Decline in Alzheimer Patients
Vitamin E given daily was effective in slowing patients’ functional decline and in reducing caregiver time.
Omega-3 May Protect Against Alzheimer Disease
Omega-3 fatty acids in dietary supplements can cross the blood-brain barrier in persons who have Alzheimer disease, affecting known markers for the disease and for inflammation, a study shows.
Sleep Problems Tied to Neurodegenerative Conditions
Brain cell damage similar to that seen in Alzheimer disease and other disorders results when a gene that controls the sleep-wake cycle and other bodily rhythms is disabled.
Use Peanut Butter to Sniff Out Early Alzheimer Disease?
Peanut butter and a ruler may turn out to be tools that offer an inexpensive, sensitive, and specific olfactory means of screening for Alzheimer disease. Details here.
Is Screening for Pre-dementia a Good Idea?
The drive to screen older persons for minor memory changes is leading to unnecessary investigation and potentially harmful treatment, according to some experts.
Alzheimer Researchers Say Share Data With Patients
As biomarkers to detect signals of Alzheimer disease improve at providing clinically meaningful information, a majority of Alzheimer researchers support disclosing results to research subjects who have these tests.
Taking Alzheimer Research Down New Protein Paths
Researchers have devoted themselves to devising ways of blocking the production or accumulation of beta-amyloid. Now scientists are studying other protein targets, including tau.
Alzheimer Risk Variants Identified With Genetic Markers
If drugs could be developed to target tau, they might prevent much of the neurodegeneration that characterizes Alzheimer disease and help prevent or delay dementia.
2 Clarke Drive Cranbury, NJ 08512